Processing

Please wait...

Settings

Settings

Goto Application

1. WO2006093143 - MODEL FOR NASH OR LIVER TUMOR, METHOD FOR PRODUCTION OF THE MODEL, METHOD FOR SCREENING OF THERAPEUTIC AGENT FOR NASH OR LIVER TUMOR, METHOD FOR ANALYSIS OF MECHANISM FOR DEVELOPMENT OF NASH OR LIVER TUMORM, AND AGENT FOR PREVENTION OR TREATMENT OF NASH

Publication Number WO/2006/093143
Publication Date 08.09.2006
International Application No. PCT/JP2006/303742
International Filing Date 28.02.2006
IPC
C12N 15/00 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
A01K 67/027 2006.01
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
67Rearing or breeding animals, not otherwise provided for; New breeds of animals
027New breeds of vertebrates
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 48/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 1/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C12N 15/09 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
CPC
A01K 2267/03
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
2267Animals characterised by purpose
03Animal model, e.g. for test or diseases
A01K 2267/0331
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
2267Animals characterised by purpose
03Animal model, e.g. for test or diseases
0331Animal model for proliferative diseases
A01K 67/0275
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
67Rearing or breeding animals, not otherwise provided for; New breeds of animals
027New breeds of vertebrates
0275Genetically modified vertebrates, e.g. transgenic
A61K 38/2264
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
2264Obesity-gene products, e.g. leptin
A61K 48/005
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
005characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Applicants
  • 学校法人 久留米大学 Kurume University [JP]/[JP] (AllExceptUS)
  • 中山 ひとみ NAKAYAMA, Hitomi [JP]/[JP] (UsOnly)
  • 小田邊 修一 OTABE, Shuichi [JP]/[JP] (UsOnly)
  • 山田 研太郎 YAMADA, Kentaro [JP]/[JP] (UsOnly)
  • 上野 隆登 UENO, Takato [JP]/[JP] (UsOnly)
  • 廣田 有俊 HIROTA, Naotoshi [JP]/[JP] (UsOnly)
Inventors
  • 中山 ひとみ NAKAYAMA, Hitomi
  • 小田邊 修一 OTABE, Shuichi
  • 山田 研太郎 YAMADA, Kentaro
  • 上野 隆登 UENO, Takato
  • 廣田 有俊 HIROTA, Naotoshi
Agents
  • 木島 智子 KIJIMA, Tomoko
Priority Data
2005-05825102.03.2005JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) MODEL FOR NASH OR LIVER TUMOR, METHOD FOR PRODUCTION OF THE MODEL, METHOD FOR SCREENING OF THERAPEUTIC AGENT FOR NASH OR LIVER TUMOR, METHOD FOR ANALYSIS OF MECHANISM FOR DEVELOPMENT OF NASH OR LIVER TUMORM, AND AGENT FOR PREVENTION OR TREATMENT OF NASH
(FR) MODÈLE POUR SHNA OU TUMEUR DU FOIE, PROCÉDÉ DE PRODUCTION DU MODÈLE, PROCÉDÉ DE CRIBLAGE D’AGENT THÉRAPEUTIQUE POUR SHNA OU TUMEUR DU FOIE, PROCÉDÉ D’ANALYSE DU MÉCANISME DE DÉVELOPPEMENT DE SHNA OR TUMEUR DU FOIE, ET AGENT DE PRÉ
(JA) NASH又は肝腫瘍モデル及びその作製方法,NASH又は肝腫瘍治療剤のスクリーニング方法,NASH又は肝腫瘍発症機序解析方法,並びにNASHの予防又は治療剤
Abstract
(EN)
[PROBLEMS] To provide a model animal which can present a symptom distinctive for non-alcoholic steatohepatitis (NASH) within a short period of time without artificially deleting a gene originally expressed in 'a hepatocyte' or a model animal for liver tumor caused by NASH; the elucidation of the mechanism for development of NASH or liver tumor; screening of an agent for the prevention or treatment of NASH or liver tumor; and an agent for the prevention or treatment of NASH. [MEANS FOR SOLVING PROBLEMS] A model animal for non-alcoholic steatohepatitis or liver tumor having a gene encoding a part or the entire of the amino acid sequence for SREBP1c having a transcriptional activity and a promoter gene capable of directing an adipose tissue-specific expression introduced therein; and an agent for preventing or treating NASH, comprising one or more substances selected from adiponectin or an analogue thereof and a gene encoding adiponectin or the analogue thereof as the active ingredient(s).
(FR)
L’invention concerne un animal modèle susceptible de présenter un symptôme distinctif de stéatohépatite non alcoolique (SHNA) dans une courte période sans effacer artificiellement un gène exprimé à l’origine dans 'un hépatocyte' ou un animal modèle pour tumeur du foie causée par SHNA ; l’élucidation du mécanisme de développement de la SHNA ou de la tumeur du foie ; le criblage d’un agent pour la prévention ou le traitement de la SHNA ou de la tumeur du foie ; et un agent pour la prévention ou le traitement de la SHNA. Elle porte sur un animal modèle pour stéatohépatite non alcoolique ou tumeur du foie ayant un gène codant pour une partie ou la totalité de la séquence d’acide aminé pour SREBP1c ayant une activité de transcription et un gène promoteur capable de diriger une expression spécifique au tissu adipose introduits dans celui-ci ; et un agent de prévention ou de traitement de la SHNA, comprenant une ou plusieurs substances sélectionnées parmi l’adiponectine ou un analogue de celle-ci et un gène codant pour l’adiponectine ou l’analogue de celle-ci comme ingrédient(s) actif(s).
(JA)
【課題】より短期に、しかも「肝細胞」内に本来発現している遺伝子を人為的に欠落させることなく、非アルコール性脂肪性肝炎(NASH)の症状を呈する動物モデルを提供,またNASHに起因する肝腫瘍動物モデルを提供,更には当該モデルを用いた、NASH又は肝腫瘍の発症機序の解明,NASH又は肝腫瘍の予防又は治療剤のスクリーニング及び、NASHの予防又は治療剤の提供。 【解決手段】SREBP1cの一部又は全部のアミノ酸配列であって、転写活性を有するアミノ酸配列をコードする遺伝子と脂肪組織特異的発現性を有するプロモーター遺伝子が導入されていることを特徴とする、非アルコール性脂肪性肝炎又は肝腫瘍動物モデル,及びアディポネクチン又はその類縁化合物,またもしくはこれらをコードする遺伝子から選択される一種又は二種以上を有効成分として含有することを特徴とする、NASHの予防又は治療剤。
Also published as
EP6728558
Latest bibliographic data on file with the International Bureau